Our immunohistochemical analysis showed that EphA5 is widely expressed in human lung cancer, particularly in squamous cell carcinoma and that those patients expressing EphA5 as a molecular marker are at much higher risk of radiotherapy failure and death. This evidence concerns the gene EPHA5 and lung carcinoma.